Overview

Friday, January 30, 2026

A CME/CNE-accreditted patient & caregiver program

7:00 am - 4:20 pm EST

In-person or virtual

Rubenstein Auditorium | Smilow Center for Translational Research
3400 Civic Center Boulevard, Philadelphia, PA 19104

Register Now

Overview

The purpose of this educational activity is to provide a review of new treatment options in neuro-oncology, including surgical techniques, and intraoperative imaging, along with, radiation and systemic therapies that have improved patient outcomes. Sessions will feature the latest advances in state-of-the-art care for practicing clinicians treating patients with brain tumors. Cutting-edge topics in precision medicine, including genetic, translational, and clinical research will also be featured. Activity format will provide significant opportunity for interaction with expert faculty and other attendees with the aim of implementing new standards of patient care. Participants will leave with up-to-date, practical information which will have immediate clinical application, as well as technical and scientific background on the current state, and where the latest scientific advances may take the field.

Who Should Attend

This symposium is designed for neurosurgeons, neurooncologists, neurologists, neuroradiologists, radiologists, medical oncologists, radiation oncologists, pathologists, primary care physicians, oncology nurses, and other healthcare professionals involved in the treatment of patients with brain tumors. Additionally, patients and their caregivers, family members, advocates and members of the public who may benefit from understanding current innovative approaches to brain tumor care are invited.

Learning Objectives

Upon completion of this course, participants should be able to:

  • Integrate next-generation sequencing (NGS) and methylation profiling data to inform personalized diagnostic, prognostic, and management decisions for patients with brain tumors, particularly gliomas and meningiomas.
  • Utilize advancements in neuroimaging, including radiogenomics and amino acid PET, to enhance diagnostic accuracy and guide clinical decision-making in the neuro-oncology clinic
  • Appraise the latest clinical trial data on novel immunotherapeutic approaches, including CAR-T cell therapy, and identify appropriate patient candidates and management considerations for these emerging treatments.
  • Incorporate the key findings from the INDIGO trial to determine the optimal timing and patient selection for Vorasidenib in the treatment of IDH-mutant low-grade gliomas.
  • Develop a practical toolkit for the comprehensive medical and symptom management of patients with brain tumors, focusing on improving their quality of life and functional status.
  • Evaluate the clinical utility of new technologies, such as liquid biopsy and intraoperative molecular imaging, for improving the diagnosis, monitoring, and surgical precision of brain tumor treatment.
  • Summarize the latest advancements in radiation therapy (protons, photons, FLASH) and targeted/immunological treatments for brain metastases to optimize patient care and improve outcomes.

For Patients, Caregivers, and Advocates:

  • Gain a clear understanding of cutting-edge treatment innovations and identify the essential resources needed to navigate the healthcare system effectively for shared decision-making.
  • Learn how to translate complex research into practical needs, access reliable support networks, and apply actionable strategies for improving quality of life throughout the brain tumor journey.

For additional information please contact Gabrielle White.